A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome

European Journal of Endocrinology

Volumn 166, Issue 1, 2012, Pages 99-105

  Wei, Wei ^a   Zhao, Hongmin ^a   Wang, Aili ^a   Sui, Ming ^a   Liang, Kun ^a   Deng, Haiyun ^a   Ma, Yukun ^a   Zhang, Yajuan ^a   Zhang, Hongxiu ^a   Guan, Yuanyuan ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; CHOLESTEROL; CYPROTERONE ACETATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SEX HORMONE BINDING GLOBULIN; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ADULT; ANTHROPOMETRY; AREA UNDER THE CURVE; ARTICLE; BITTER TASTE; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; NAUSEA; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

BERBERINE; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HUMANS; INSULIN RESISTANCE; METFORMIN; POLYCYSTIC OVARY SYNDROME; TRIGLYCERIDES; WAIST CIRCUMFERENCE; WAIST-HIP RATIO;

EID: 84055184743     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0616     Document Type: Article

References (44)

1. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 2004 81 19-252.
2. Orio F Jr, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G & Colao A. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. Journal of Clinical Endocrinology and Metabolism 2004 89 3696-3701. (doi:10.1210/jc.2003-032049)
3. Robert A. Wild. Long-term health consequences of PCOS. Human Reproduction Update 2002 8 231-241. (doi:10.1093/humupd/8.3.231)
4. Manneras-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, Lonn M & Stener-Victorin E. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2011 96 1068-1076. (doi:10.1210/jc.2010-2279)
5. Legro RS, Castracane VD & Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstetrical and Gynecological Survey 2004 59 141-154. (doi:10.1097/01.OGX.0000109523.25076.E2)
6. DeUgarte CM, Bartolucci AA & Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertility and Sterility 2005 83 1454-1460. (doi:10.1016/j. fertnstert.2004.11.070)
7. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J & Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine 2004 10 1344-1351. (doi:10.1038/nm1135)
8. Eisenhardt S, Schwarzmann N, Henschel V, Germeyer A, Wolff M, Hamann A & Strowitzki T. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2006 91 946-952. (doi:10.1210/jc.2005-1994)
9. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L &David SG. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. Journal of Clinical Endocrinology and Metabolism 2008 93 4299-4306. (doi:10.1210/jc.2008-0461)
10. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G & Panidis D. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Human Reproduction 2006 21 1426-1431. (doi:10.1093/humrep/del003)
11. Trolle B, Flyvbjerg A, Kesmodel U & Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Human Reproduction 2007 22 2967-2973. (doi:10.1093/humrep/dem271)
12. Harborne LR, Sattar N, Norman JE & Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. Journal of Clinical Endocrinology and Metabolism 2005 90 4593-4598. (doi:10.1210/jc.2004-2283)
13. Macut D, Panidis D, Glisic B, Spanos N, Petakov M, Bjekic J, Stanojlovic O, Rousso D, Kourtis A, Bozic I & Damjanovic S. Lipid and lipoprotein profile in women with polycystic ovary syndrome. Canadian Journal of Physiology and Pharmacology 2008 86 199-204. (doi:10.1139/Y08-014)
14. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT, Hohnen-Behrens C, Gosby A, Kraegen EW, James DE & Kim JB. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes Care 2006 55 2256-2264. (Pubitemid 44743622)
15. Yin J, Xing H & Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008 57 712-717. (doi:10.1016/j.metabol.2008.01. 013)
16. Gu Y, Shi X, Li X, Hong J, Chen J, Gu W, Lu X, Xu G & Ning G. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta 2010 81 766-772. (doi:10.1016/j.talanta. 2010.01.015)
17. Yin J, Gao Z, Liu D, Liu Z & Ye J. Berberine improves glucose metabolism through induction of glycolysis. American Journal of Physiology. Endocrinology and Metabolism 2008 294 E148-E156. (doi:10.1152/ajpendo.00211. 2007)
18. Ascaso JF, Romero P, Real JT, Lorente RI, Martinez-Valls J &Carmena R. Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. European Journal of Internal Medicine 2003 14 101-106. (doi:10.1016/S0953-6205(03)00022-0)
19. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ & Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. New England Journal of Medicine 2004 351 2599-2610. (doi:10.1056/NEJMoa040967)
20. Hatch R, Rosenfield RL, Kim MH & Tredway D. Hirsutism: implications, etiology, and management. American Journal of Obstetrics and Gynecology 1981 140 815-830. (Pubitemid 11046650)
21. Laven JS, Imani B, Eijkemans MJ & Fauser BC. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstetrical and Gynecological Survey 2002 57 755-767. (doi:10.1097/00006254- 200211000-00022)
22. Yue J. Obstetrics and gynecology. People's Medical Publishing House, 6th edn, ch 46, p 418. Peking: Xinhua Book Store, 2004.
23. Balen AH, Laven JS, Tan SL & Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Human Reproduction Update 2003 9 505-514. (doi:10.1093/humupd/dmg044)
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF &Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419. (doi:10.1007/BF00280883)
25. Legro RS, Finegood D & Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1998 83 2694-2698. (doi:10.1210/jc.83.8.2694)
26. Mathur S, Baker ER, Williamson HO, Derrick FC, Teague KJ &Fudenberg HH. Clinical significance of sperm antibodies in infertility. Fertility and Sterility 1981 36 486-495. (Pubitemid 11027023)
27. WHO Technical Report Series, No. 646, 1980 (Second report of the WHO Expert Committee on Diabetes Mellitus).
28. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA &Stern MP. Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 1992 41 715-722. (doi:10.2337/diabetes.41.6.715)
29. Pasquali R, Gambineri A, Cavazza C, Ibarra Gasparini D, Ciampaglia W, Cognigni GE & Pagotto U. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. European Journal of Endocrinology 2011 164 53-60. (doi:10.1530/EJE-10- 0692)
30. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK &Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility 2004 82 421-429. (doi:10.1016/j.fertnstert.2004.02.104)
31. Norman RJ, Davies MJ, Lord J & Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends in Endocrinology and Metabolism 2002 13 1630-1635.
32. Luque-Ramirez M & Escobar-Morreale HF. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. Hormone and Metabolic Research 2010 42 815-820. (doi:10.1055/s-0030-1262855)
33. Lord J, Thomas R, Fox B, Acharya U & Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome - a randomised, double-blind, placebo-controlled trial. British Journal of Obstetrics and Gynaecology 2006 113 817-824. (doi:10.1111/j.1471-0528.2006.00966.x)
34. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD & Kim JB. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. American Journal of Physiology. Endocrinology and Metabolism 2009 296 E812-E819. (doi:10.1152/ajpendo.90710.2008)
35. Vuddanda PR, Chakraborty S & Singh S. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opinion on Investigational Drugs 2010 19 1297-1307. (doi:10.1517/13543784.2010.517745)
36. Chen C, Zhang Y & Huang C. Berberine inhibits PTP1B activity and mimics insulin action. Biochemical and Biophysical Research Communications 2010 397 543-547. (doi:10.1016/j.bbrc.2010.05.153)
37. Zhang YF, Li XY, Zou DJ, Liu W, Yang JL, Zhu N, Huo L, Wang M, Hong J, Wu PH, Ren GG & Ning G. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. Journal of Clinical Endocrinology and Metabolism 2008 93 2559-2565. (doi:10.1210/jc.2007-2404)
38. Zhou L, Yang Y, Wang X, Liu S, Shang W, Yuan G, Li F, Tang J, Chen M & Chen J. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 2007 56 405-412. (doi:10.1016/j.metabol.2006. 10.025)
39. Cheng Z, Pang T, Gu M, Gao AH, Xie CM, Li JY, Nan FJ & Li J. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochimica et Biophysica Acta 2006 760 1682-1689. (Pubitemid 44667275)
40. Yin J, Hu R, Chen M, Tang J, Li F, Yang Y & Chen J. Effects of berberine on glucose metabolism in vitro. Metabolism 2002 51 1439-1443. (doi:10.1053/meta.2002.34715)
41. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, Taketo MM, Cooney GJ, Kraegen EW, James DE, Hu LH, Li J &Ye JM. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008 57 1414-1418. (doi:10.2337/db07-1552)
42. Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y & Issandou M. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. Journal of Lipid Research 2006 47 1281-1288. (doi:10.1194/jlr.M600020-JLR200)
43. Zhao L, Han F, Hou L, Baillargeon JP, Kuang H, Wang Y & Wu X. Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. Fertility and Sterility 2011 95 461-463. (doi:10.1016/j.fertnstert.2010. 07.1090)
44. Zuo F, Nakamura N, Akao T & Hattori M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metabolism and Disposition 2006 34 2064-2072. (doi:10.1124/dmd.106.011361)